chronic pain News
-
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. There is a high unmet medical need in chronic pain, particularly among ...
By Camurus AB
-
Robotic innovation delivers relief for back pain sufferers
An innovation that automates the diagnosis and treatment of chronic back pain could bring benefits to millions of patients, increase work productivity and provide therapists with a time-saving ...
By Adamo Robot
-
10 Fascinating Facts About Myofascial Release (MFR)
Myo + Fascial + Release, or MFR Myo, meaning muscle, and fascia, the main connective tissue, account for almost all soft tissue in the body. That soft tissue can become damaged, creating restrictions which limit movement and create pain. “Release” refers to the gentle way in which myofascial release uses the natural qualities of fascia to release those restrictions, restoring ...
By DSmedi, Inc.
-
Targeting Alternative Opioid Receptor Reduces Drug Side Effects
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used cells from humans and mice with inammatory bowel ...
-
Nevro to Present at Citi`s 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern ...
By Nevro Corp.
-
Physiotherapy for back pain with a contactless AI robot - Spain Adamo Robot
The protocol for the treatment of chronic back pain is difficult to establish, but certain results of physical therapy are expected. A fully automated physical therapy robot has been developed to promote the use of physical therapy and improve the productivity of physical ...
By Adamo Robot
-
Saluda Medical Announces Executive Leadership Changes
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. Mr. Schuermann joined Saluda Medical as President in June 2020. The company also announced that founder and CEO John ...
-
Nalu Medical Releases Latest Software Upgrade to Expand Nalu Neurostimulation System Capabilities
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the treatment of intractable chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), announced the release of their latest software upgrade that adds new capabilities to their micro neurostimulation system. Like a smartphone ...
-
Panag Pharma Inc. Announces Initiation Of A Clinical Trial
Halifax, Nova Scotia. Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health product indicated for temporary relief of aches and pains of muscles and joints associated with simple backache, lumbago, ...
-
Saluda Medical Announces $125M Equity Financing Led by Redmile Group LLC and New Investors Fidelity Management & Research Company LLC and T. Rowe Price Associates, Inc.
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as ...
-
Panag Pharma Announces Health Canada License for Topical A OTC (NPN 80070485)
Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Topical AOTC uses a novel technology targeting the ...
-
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro`s HF10® Therapy
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized ...
By Nevro Corp.
-
Panag Pharma announces health Canada License for a topical cold-sore formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated ...
-
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro`s 10 kHz Therapy
SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 18-Months Follow-Up. SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. Both SENZA-PDN and SENZA-NSRBP Studies ...
By Nevro Corp.
-
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results
Company to Host Conference Call on Wednesday, February 23, 2022 at 1:30 pm PT / 4:30 pm ET. REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ...
By Nevro Corp.
-
Presidio MedicalTM Announces Publication of ULFTM Neuromodulation Research in Science Translational Medicine
SOUTH SAN FRANCISCO, Calif., August 25, 2021 – Presidio Medical, Inc., a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the company’s novel ULF™ neuromodulation therapy has been published in Science Translational Medicine. The publication, titled “Neuromodulation using ultra low ...
-
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), in July 2020 received clearance from the U.S. Food and Drug Administration (FDA) of an expanded label for its micro-Implantable Pulse Generator (mIPG) to an ...
-
Gelexir becomes Gelmetix
We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix. This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: ...
-
Panag Pharma Announces Patent Grant
Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations. Panag Pharma’s ocular formulation leverages a novel drug platform ...
-
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million. Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End of Previously Provided Fourth Quarter 2021 Non-GAAP Adjusted EBITDA Guidance Company to Present Today at J.P. Morgan Healthcare Conference at 4:30 pm Eastern Time. REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. ...
By Nevro Corp.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you